AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29775954 — intervention group
Group type: COMPARATOR
Intervention: Control group with conventional physical therapy protocol
Number of subjects: 30
Study 28418172 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam 20 mg
Number of subjects: 49
Study 28418172 — intervention group
Group type: COMPARATOR
Intervention: Active placebo tolterodine 1 mg
Number of subjects: 49
Study 25661312 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascia Iliaca Compartment Block (FICB) using lidocaine with epinephrine
Number of subjects: 24
Study 25661312 — intervention group
Group type: COMPARATOR
Intervention: Standard care (further intravenous morphine only)
Number of subjects: 24
Study 23301896 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg ginseng twice daily for 3 months
Number of subjects: 60
Study 23301896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21129375 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon (half-dose)
Number of subjects: 1048
Study 21129375 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 1048
Study 21129375 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon (for patients with cirrhosis)
Number of subjects: 1048
Study 21129375 — intervention group
Group type: COMPARATOR
Intervention: Control (for patients with cirrhosis)
Number of subjects: 1048
Study 21129375 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon (for patients with fibrosis)
Number of subjects: 1048
Study 21129375 — intervention group
Group type: COMPARATOR
Intervention: Control (for patients with fibrosis)
Number of subjects: 1048
Study 21129375 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon (for patients with a ≥ 2-point decrease in histologic activity index)
Number of subjects: 1048
Study 21129375 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon (for patients with unchanged or increased histologic activity index)
Number of subjects: 1048
Study 18351194 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-directed intervention (e-mails and nurse telephone calls)
Number of subjects: 334
Study 18351194 — intervention group
Group type: COMPARATOR
Intervention: Reminder-only (computerized reminders)
Number of subjects: 334
Study 18351194 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-directed intervention (in subgroup with no aspirin use at baseline)
Number of subjects: 334
Study 18351194 — intervention group
Group type: COMPARATOR
Intervention: Reminder-only (in subgroup with no aspirin use at baseline)
Number of subjects: 334
Study 16554198 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 31
Study 16554198 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 31
Study 14600858 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 20 microg/kg
Number of subjects: 102
Study 14600858 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar anaesthesia (Mepivacain 2 %/Bupivacain 0.5 %)
Number of subjects: 102
Study 14600858 — intervention group
Group type: COMPARATOR
Intervention: Dolasetron 12.5 mg
Number of subjects: 102
Study 14600858 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 8 mg
Number of subjects: 102
Study 14600858 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9 %)
Number of subjects: 102
Study 10913923 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CTX measured in the early afternoon (1-2 PM)
Number of subjects: 854
Study 10913923 — intervention group
Group type: COMPARATOR
Intervention: Urinary CTX
Number of subjects: 854
Study 10913923 — intervention group
Group type: COMPARATOR
Intervention: Free deoxypyridinoline
Number of subjects: 854
Study 10913923 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CTX from morning samples
Number of subjects: 854
Study 7778963 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient GEM team clinic
Number of subjects: 128
Study 7778963 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 128
Study 2224663 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 104
Study 2224663 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin plus clindamycin or metronidazole (Control)
Number of subjects: 104
Study 39585 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg propranolol
Number of subjects: 9
Study 39585 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol
Number of subjects: 9
Study 39585 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg propranolol and 100 mg metoprolol
Number of subjects: 9
Study 31051322 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy – Adolescent Skills Training (IPT‐AST)
Number of subjects: 167
Study 31051322 — intervention group
Group type: COMPARATOR
Intervention: Group Counseling (GC)
Number of subjects: 167
Study 28904084 — intervention group
Group type: EXPERIMENTAL
Intervention: SV runs group
Number of subjects: 254
Study 28904084 — intervention group
Group type: EXPERIMENTAL
Intervention: pAF detected after cerebral ischemia
Number of subjects: 254
Study 28904084 — intervention group
Group type: COMPARATOR
Intervention: Controls (no SV runs)
Number of subjects: 254
Study 25959196 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice daily)
Number of subjects: 50
Study 25959196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 24579278 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo mechanical (carie care) caries removal method
Number of subjects: 20
Study 24579278 — intervention group
Group type: COMPARATOR
Intervention: Airotor hand instruments
Number of subjects: 20
Study 20842070 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414 vaccine
Number of subjects: 100
Study 20842070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 18316395 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate daily alcohol consumption (16.4‐42.6 g ethanol/day)
Number of subjects: 8576
Study 18316395 — intervention group
Group type: COMPARATOR
Intervention: Nondrinkers with the highest GGT
Number of subjects: 8576
Study 18316395 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate or heavy alcohol drinkers (>or=42.7 g ethanol/day)
Number of subjects: 8576
Study 18316395 — intervention group
Group type: EXPERIMENTAL
Intervention: GGT and ALT levels
Number of subjects: 8576
Study 18316395 — intervention group
Group type: COMPARATOR
Intervention: Nondrinkers with the highest GGT or ALT
Number of subjects: 8576
Study 16602254 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO2 treatment at 2.4 atm abs pressure with 90 minutes of 100% oxygen breathing
Number of subjects: 30
Study 16602254 — intervention group
Group type: COMPARATOR
Intervention: US Air Force CO protocol (3.0 atm abs maximum pressure)
Number of subjects: 30
Study 12963554 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric acid-lowering medications (histamine receptor H2 antagonists or proton pump inhibitors)
Number of subjects: 0
Study 12963554 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving gastric acid-lowering medications)
Number of subjects: 0
Study 9049782 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraglobin-F
Number of subjects: 27
Study 9049782 — intervention group
Group type: COMPARATOR
Intervention: Sandoglobulin
Number of subjects: 27
Study 9049782 — intervention group
Group type: COMPARATOR
Intervention: Gamimune-N, Sandoglobulin, Gammagard
Number of subjects: 27
Study 8290213 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% cyclopentolate hydrochloride for 1 week postoperatively
Number of subjects: 160
Study 8290213 — intervention group
Group type: COMPARATOR
Intervention: Noncycloplegic group
Number of subjects: 160
Study 8290213 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall postoperative flare
Number of subjects: 160
Study 3494005 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic irradiation followed by a prostate boost
Number of subjects: 526
Study 3494005 — intervention group
Group type: COMPARATOR
Intervention: Pelvic and periaortic irradiation followed by a prostate boost
Number of subjects: 526
Study 3494005 — intervention group
Group type: EXPERIMENTAL
Intervention: Doses to the prostate in excess of 7000 cGy
Number of subjects: 526
Study 3494005 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic irradiation techniques
Number of subjects: 526
Study 3494005 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral boost technique and perineal boost technique
Number of subjects: 526
Study 3494005 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dose to the regional lymphatics (4400 to 5100 cGy)
Number of subjects: 526
Study 29797500 — intervention group
Group type: EXPERIMENTAL
Intervention: real‐rTMS (for five consecutive days in 20‐min sessions)
Number of subjects: 15
Study 29797500 — intervention group
Group type: COMPARATOR
Intervention: sham‐rTMS (for five consecutive days in 20‐min sessions)
Number of subjects: 15
Study 26695388 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse ratio ventilation (IRV) with I:E ratio of 2:1
Number of subjects: 60
Study 26695388 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation with I:E ratio of 1:2
Number of subjects: 60
Study 24621025 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 17
Study 24621025 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 17
Study 24621025 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of VAS scores and patient satisfaction
Number of subjects: 17
Study 22499965 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Impact for 5 days before surgery
Number of subjects: 30
Study 22499965 — intervention group
Group type: COMPARATOR
Intervention: Conventional diet before surgery
Number of subjects: 30
Study 20045497 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin (simvastatin, moderate to high dose)
Number of subjects: 212
Study 20045497 — intervention group
Group type: COMPARATOR
Intervention: Non-statin therapy
Number of subjects: 212
Study 17901413 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 62.5 mg twice daily for 4 weeks, increased to 125 mg twice daily thereafter for 12 months
Number of subjects: 158
Study 17901413 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 158
Study 17901413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 15486003 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine, 20 microg kg(‐1)
Number of subjects: 40
Study 15486003 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil, 1 microg kg(‐1) injected over 60 s, followed by infusion of 0.25 microg kg(‐1) min(‐1) for 10 min then 0.5 microg kg(‐1) min(‐1) for 10 min
Number of subjects: 40
Study 15486003 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate (control group)
Number of subjects: 40
Study 15486003 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 40
Study 12202963 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose clonidine (2.5 mg/kg)
Number of subjects: 10
Study 12202963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10489843 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (100 microg or 200 microg daily)
Number of subjects: 163
Study 10489843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 8998488 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36
Number of subjects: 380
Study 8998488 — intervention group
Group type: EXPERIMENTAL
Intervention: Euroqol
Number of subjects: 380
Study 8998488 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCS Disability Survey
Number of subjects: 380
Study 1728438 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg p.o.)
Number of subjects: 20
Study 1728438 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 42-5892 (600 mg p.o.)
Number of subjects: 20
Study 6731326 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (beta 1-selective blocker), administered intravenously followed by oral treatment for 3 months.
Number of subjects: 1395
Study 30988169 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-TnT)
Number of subjects: 12310
Study 30988169 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide (NT-proBNP)
Number of subjects: 12310
Study 30988169 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hs-CRP)
Number of subjects: 12310
Study 29487995 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI) + renal artery denervation (RDN)
Number of subjects: 138
Study 29487995 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 138
Study 26994823 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strength and proprioception training (CSPT) program
Number of subjects: 20
Study 26994823 — intervention group
Group type: COMPARATOR
Intervention: Daily activities (Control)
Number of subjects: 20
Study 25509693 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 400 IU twice daily
Number of subjects: 37
Study 25509693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 22490110 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored feedback programme
Number of subjects: 0
Study 22490110 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored feedback programme + prompts (e-mail and SMS)
Number of subjects: 0
Study 22490110 — intervention group
Group type: COMPARATOR
Intervention: No information control condition
Number of subjects: 0
Study 20580752 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 38
Study 20580752 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 38
Study 18717113 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Number of subjects: 0
Study 18717113 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine
Number of subjects: 0
Study 18717113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15987349 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusion trigger level < 10 x 10(9) PLTs per L (T10; n = 79)
Number of subjects: 166
Study 15987349 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic platelet transfusion trigger level < 30 x 10(9) PLTs per L (T30; n = 87)
Number of subjects: 166
Study 15987349 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusion trigger level < 10 x 10(9) PLTs per L (T10)
Number of subjects: 166
Study 15987349 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic platelet transfusion trigger level < 30 x 10(9) PLTs per L (T30)
Number of subjects: 166
Study 12454557 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon 10 mg
Number of subjects: 30
Study 12454557 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon 20 mg
Number of subjects: 30
Study 12454557 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 30
Study 12454557 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg
Number of subjects: 30
Study 12454557 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.03% < BAC < 0.05%)
Number of subjects: 30
Study 12454557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10473803 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Number of subjects: 0
Study 10473803 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte/macrophage-colony stimulating factor (GM-CSF)
Number of subjects: 0
Study 8768856 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-386 (10-100 mg)
Number of subjects: 26
Study 8768856 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg)
Number of subjects: 26
Study 8768856 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg) + MK-386 (25 mg)
Number of subjects: 26
Study 1725915 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (12.5 mg once daily, then 25 mg once daily, and finally 25 mg twice daily)
Number of subjects: 369
Study 1725915 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg once daily, then 240 mg once daily, and finally 240 mg twice daily)
Number of subjects: 369
Study 1725915 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hydrochlorothiazide and verapamil (25 mg and 240 mg once daily and twice daily)
Number of subjects: 369
Study 1725915 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 369
Study 6789593 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 0
Study 6789593 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotrophin releasing hormone (TRH)
Number of subjects: 0
Study 30612463 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day Coenzyme Q10 and 500 mg/day L-carnitine for 8 weeks
Number of subjects: 56
Study 27762093 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg
Number of subjects: 482
Study 27762093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 482
Study 26850413 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care with a care manager (PCM)
Number of subjects: 404
Study 26850413 — intervention group
Group type: COMPARATOR
Intervention: Minimally enhanced usual care (MEU)
Number of subjects: 404
Study 26850413 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaged in care management
Number of subjects: 404
Study 24433285 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat (10 mg/day for weeks 1-4, 20 mg/day for weeks 5-8, 40 mg/day from week 9 to week 108)
Number of subjects: 400
Study 24433285 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 400
Study 24433285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 22845636 — intervention group
Group type: EXPERIMENTAL
Intervention: One-to-one interaction process with group supportive psychotherapy
Number of subjects: 80
Study 22845636 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study 19261341 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental treatment
Number of subjects: 30
Study 19261341 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dental treatment)
Number of subjects: 30
Study 17270577 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation-based stress management program
Number of subjects: 0
Study 17270577 — intervention group
Group type: COMPARATOR
Intervention: Anxiety disorder education program
Number of subjects: 0
Study 15589377 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 500 mg/day
Number of subjects: 33
Study 15589377 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 1000 mg/day
Number of subjects: 33
Study 15589377 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 12419152 — intervention group
Group type: EXPERIMENTAL
Intervention: BAG (bioactive glass) group
Number of subjects: 10
Study 12419152 — intervention group
Group type: COMPARATOR
Intervention: OFD (open flap debridement) group
Number of subjects: 10
Study 9459341 — intervention group
Group type: EXPERIMENTAL
Intervention: Allele II
Number of subjects: 112
Study 9459341 — intervention group
Group type: EXPERIMENTAL
Intervention: Ala601‐Thr mutation on allele I
Number of subjects: 112
Study 7657809 — intervention group
Group type: EXPERIMENTAL
Intervention: rPDGF-BB
Number of subjects: 0
Study 2536288 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy maintenance with MACC regimen (38 subjects)
Number of subjects: 116
Study 2536288 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy discontinuation (36 subjects)
Number of subjects: 116
Study 27992256 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor conditioning of the nondominant leg (4 sessions/wk; 3 wk)
Number of subjects: 23
Study 27992256 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (no conditioning)
Number of subjects: 23
Study 29071382 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES) 130/0.4
Number of subjects: 90
Study 29071382 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid
Number of subjects: 90
Study 26327527 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine
Number of subjects: 64
Study 26327527 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375% bupivacaine
Number of subjects: 64
Study 26327527 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 64
Study 23342337 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-retained overdenture (IOD) group
Number of subjects: 60
Study 23342337 — intervention group
Group type: COMPARATOR
Intervention: Relined conventional denture (RCD) group
Number of subjects: 60
Study 23342337 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 20953817 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels in the fourth quartile
Number of subjects: 2974
Study 20953817 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP level as a continuous variable
Number of subjects: 2974
Study 20953817 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline CRP levels
Number of subjects: 2974
Study 20953817 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing quartiles of CRP in troponin-positive patients
Number of subjects: 2974
Study 18163409 — intervention group
Group type: EXPERIMENTAL
Intervention: People with Arthritis Can Exercise (PACE) program
Number of subjects: 346
Study 18163409 — intervention group
Group type: EXPERIMENTAL
Intervention: People with Arthritis Can Exercise (PACE) program (attended >=9 classes)
Number of subjects: 346
Study 16733670 — intervention group
Group type: EXPERIMENTAL
Intervention: Kalèdo board-game intervention (15-30 minute sessions once a week for 24 weeks)
Number of subjects: 241
Study 16733670 — intervention group
Group type: COMPARATOR
Intervention: Control group (no play sessions with Kalèdo)
Number of subjects: 241
Study 14563577 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency revascularization (ERV)
Number of subjects: 302
Study 14563577 — intervention group
Group type: COMPARATOR
Intervention: Initial medical stabilization (IMS)
Number of subjects: 302